Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.

BMC Cancer · 2025 · PMC12143064 · PMID 40481442

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, it is worth noting that patients whose malignant ascites VEGF levels dropped significantly after therapy with bevacizumab showed a trend toward increased event-free survival.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.